What is Dishman Pharmaceuticals & Chemicals . - (Amalgamated) share price return in the past 10 years?

Data is not available for this company

What is the P/E ratio of Dishman Pharmaceuticals & Chemicals . - (Amalgamated)?

The latest standalone P/E ratio of Dishman Pharmaceuticals & Chemicals . - (Amalgamated) as of 01-Jan-1970 is 74.11.

What is the P/B ratio of Dishman Pharmaceuticals & Chemicals . - (Amalgamated)?

The latest standalone P/B ratio of Dishman Pharmaceuticals & Chemicals . - (Amalgamated) as of 01-Jan-1970 is 1.02.

What is the 52-week high and low of Dishman Pharmaceuticals & Chemicals . - (Amalgamated)?

The 52-week high of Dishman Pharmaceuticals & Chemicals . - (Amalgamated) is Rs. 304.30 and the 52-week low is Rs. 278.10.

What is the TTM revenue of Dishman Pharmaceuticals & Chemicals . - (Amalgamated)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dishman Pharmaceuticals & Chemicals . - (Amalgamated) is Rs. 416.79 (Cr.).

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) - Stock Valuation and Financial Performance

Name: Dishman Pharmaceuticals & Chemicals . - (Amalgamated)
Brand: Dishman Pharmaceuticals & Chemicals . - (Amalgamated)

BSE: 532526 | NSE: DISHMAN | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Dishman Pharma(Amalg

Based on:

Data

M-Cap below 100cr DeciZen not available

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

74.11

Market Cap:

4,858.8 Cr.

52-wk low:

278.1

52-wk high:

304.3

Is an attractive stock to invest in?

1. Is a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) is a average quality company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Dishman Pharma(Amalg:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	TTM
ROCE % ⓘ	14.1%	12.9%	15.7%	11.6%	7.9%	10.6%	12.3%	14.7%	12.4%	12.6%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	275	359	416	353	421	463	485	473	492	510	417
Sales YoY Gr.	-	30.5%	15.8%	-15.2%	19.3%	10.1%	4.6%	-2.3%	4%	3.7%	-
Adj EPS ⓘ	3.8	3.7	6.3	4.3	2.4	3.2	4.1	5.3	3.3	5.2	4.1
YoY Gr.	-	-1.9%	71.5%	-32.7%	-43.2%	31%	30.3%	28.3%	-38.1%	59.2%	-
BVPS (₹) ⓘ	18.5	28.3	34	37.8	39.6	41.6	44.8	49.3	51.7	56.4	295.5
Adj Net Profit ⓘ	54.2	58.9	102	68.8	39.1	51.1	66.7	85.6	53	84.2	66
Cash Flow from Ops. ⓘ	21.2	42.5	90.8	110	118	250	28.3	126	14.5	125	-
Debt/CF from Ops. ⓘ	14.1	6.2	3.2	4	4.8	2	18.5	4.2	43.4	5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7.1%	3.9%	1.7%	3.7%
Adj EPS ⓘ	3.7%	16.6%	8.1%	59.2%
BVPSⓘ	13.2%	7.3%	7.9%	9%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	TTM
Return on Equity % ⓘ	24.6	16.3	20.3	11.8	6.2	7.8	9.5	11.2	6.5	9.6	2.3
Op. Profit Mgn % ⓘ	25.7	25.6	36.1	33.3	24	33.4	36	37.2	30.1	33.5	32.5
Net Profit Mgn % ⓘ	19.7	16.4	24.6	19.5	9.3	11	13.8	18.1	10.8	16.5	15.7
Debt to Equity ⓘ	1.1	0.6	0.5	0.7	0.9	0.7	0.7	0.7	0.8	0.7	-
Working Cap Days ⓘ	325	307	270	347	417	436	406	467	564	638	287
Cash Conv. Cycle ⓘ	183	168	133	101	79	61	53	50	85	91	118

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

	Standalone	Consolidated
TTM EPS (₹)	4.1	10
TTM Sales (₹ Cr.)	417	1,609
BVPS (₹.) ⓘ	295.5	103.5
Reserves (₹ Cr.) ⓘ	4,737	1,638
P/BV ⓘ	1.02	2.91
PE ⓘ	74.11	30.15

From the Market
52 Week Low / High (₹)	278.10 / 304.30
All Time Low / High (₹)	16.25 / 346.25
Market Cap (₹ Cr.)	4,859
Equity (₹ Cr.)	32.3
Face Value (₹)	2
Industry PE ⓘ	43

Management X-Ray of Dishman Pharma(Amalg:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

35.76

30.31

17.26

11.46

2.46

2.42

0.57

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Dishman Pharma(Amalg

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Dishman Pharma(Amalg

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16
Sales	275.24	359.20	415.88	352.61	420.82	463.40	484.64	473.29	492.24	510.39
Operating Expenses ⓘ	204.53	272	279.48	235.34	320.13	318.52	315.49	297.07	344.07	339.61
Manufacturing Costs	31.62	34.90	41.34	42.58	42	44.86	49.23	42.23	49.18	53.81
Material Costs	133.21	183.82	172.05	138.15	210.45	195.22	179.20	175.72	213.84	194.50
Employee Cost	18.05	24.60	25.28	28.64	47.10	45.22	58.21	58.38	58.88	65.89
Other Costs ⓘ	21.64	28.68	40.81	25.97	20.59	33.21	28.85	20.74	22.17	25.41
Operating Profit ⓘ	70.72	87.20	136.40	117.27	100.69	144.88	169.14	176.21	148.17	170.78
Operating Profit Margin (%)	25.7%	24.3%	32.8%	33.3%	23.9%	31.3%	34.9%	37.2%	30.1%	33.5%
Other Income ⓘ	16.01	11.99	5.40	12.69	16.39	11.84	13.63	55.98	67.91	62.38
Interest ⓘ	7.69	9.76	26.96	29.91	40.53	57.54	52.74	69.22	68.13	68.66
Depreciation ⓘ	14.24	16.82	19.79	20.64	28.01	31.66	35.34	44.13	44.13	44.25
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	64.80	72.61	95.06	79.41	48.54	67.52	94.70	118.84	103.82	120.25
Tax ⓘ	2.89	11.23	2.50	9.04	8.41	22.68	31.52	32.05	45.34	33.10
Profit After Tax	61.91	61.38	92.56	70.37	40.12	44.84	63.18	86.79	58.48	87.15
PAT Margin (%)	22.5%	17.1%	22.3%	20.0%	9.5%	9.7%	13.0%	18.3%	11.9%	17.1%
Adjusted EPS (₹)	4.3	3.9	5.7	4.4	2.5	2.8	3.9	5.4	3.6	5.4
Dividend Payout Ratio (%)	12%	13%	10%	14%	24%	22%	15%	11%	28%	19%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16
Equity and Liabilities
Shareholders Fund	269.24	453.79	553.62	612.96	641.38	673.63	725.41	797.08	836.43	911.50
Share Capital ⓘ	14.44	15.94	16.14	16.14	16.14	16.14	16.14	16.14	16.14	16.14
Reserves ⓘ	254.79	437.85	537.48	596.82	625.24	657.49	709.28	780.94	820.29	895.36
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	298.45	262.51	290.52	434.06	488.55	429.69	459.04	416.46	505.55	542.51
Long Term Debt	298.45	262.51	290.52	434.06	308.91	301.68	274.53	239.74	242.96	274.43
Short Term Debt	0	0	0	0	179.65	128.01	184.51	176.72	262.59	268.08
Trade Payables	40.64	46.27	22.92	75.06	119.01	84.93	95.27	83.63	99.59	76.10
Others Liabilities ⓘ	80	62.66	43.73	58.67	228.53	253.43	219.33	259.65	376.51	344.54
Total Liabilities ⓘ	688.33	825.22	910.79	1,180.76	1,477.47	1,441.68	1,499.05	1,556.81	1,818.08	1,874.65
Fixed Assets
Gross Block	259.78	326.33	358.73	464.18	624.64	639.35	886.14	942.27	986.48	1,006.35
Accumulated Depreciation	54.70	70.70	90.13	110.34	137.86	169.02	203.59	247.65	292.86	336.72
Net Fixed Assetsⓘ	205.08	255.63	268.60	353.84	486.77	470.32	682.55	694.61	693.62	669.63
CWIP ⓘ	49.10	110.62	172.96	267.64	198.96	257.34	48.79	9.86	10.15	22.14
Investmentsⓘ	131.29	132.51	156.37	181.99	187.14	187.06	187.06	187.06	210.16	250.78
Inventories	98.65	120.63	116.32	99.75	124.25	119.13	127.76	133.86	171.90	145.37
Trade Receivables	120.72	111.50	61.55	70.24	126.97	96.46	62.79	69.42	97.65	87.87
Cash Equivalents	4.95	4.49	3.20	4.28	4.31	6.45	10.89	11.26	22.62	9.27
Others Assetsⓘ	78.53	89.85	131.78	203.01	349.07	304.92	379.21	450.75	611.98	689.59
Total Assets ⓘ	688.33	825.22	910.79	1,180.76	1,477.47	1,441.68	1,499.05	1,556.81	1,818.08	1,874.65

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16
Cash Flow From Operating Activity ⓘ	21.17	42.45	90.83	109.64	117.89	249.72	28.29	125.70	14.51	124.94
PBT ⓘ	64.80	72.61	95.06	79.41	48.54	67.52	94.70	118.84	103.83	120.25
Adjustment ⓘ	15.64	13.36	47.15	40.54	54.17	77.17	80.47	54.14	54.22	53.35
Changes in Working Capital ⓘ	-54.01	-35.08	-41.31	5.73	24.94	112.61	-130.57	-22.21	-112.68	-7.77
Tax Paid ⓘ	-5.18	-8.36	-9.94	-17.14	-9.75	-7.59	-16.30	-25.06	-30.86	-40.89
Cash Flow From Investing Activity ⓘ	-194.49	-118.98	-100.51	-213.69	-190.76	-52.26	5.67	-47.54	-35.81	-30.22
Capex	-80.03	-128.86	-79.65	-196.89	-197.22	-43.74	11.84	-92.93	-59.21	-38.83
Net Investments	-119.26	7.23	0	0.05	0	0.96	0	0	3.02	0
Others ⓘ	4.79	2.65	-20.86	-16.85	6.47	-9.48	-6.17	45.39	20.38	8.61
Cash Flow From Financing Activityⓘ	54.23	76.07	8.39	105.13	72.89	-195.32	-29.84	-78.44	25.37	-102.44
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	162.70	37.33	-66.47	-59.25	10	19.38	-5.94
Interest Paid ⓘ	-6.11	-9.76	-31.69	-33.14	-39.97	-55.13	-52.52	-69.39	-68.55	-69.73
Dividend Paid ⓘ	-4.82	-7.63	-8.07	-9.68	-9.68	-9.68	-9.68	-9.68	-9.68	-32.27
Others ⓘ	65.16	93.46	48.16	-14.74	85.22	-64.03	91.61	-9.36	84.22	5.50
Net Cash Flow ⓘ	-119.08	-0.46	-1.29	1.08	0.03	2.14	4.12	-0.28	4.07	-7.72

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16
Ratios
ROE (%)	28.44	17.1	18.5	12.13	6.42	6.84	9.05	11.43	7.17	9.99
ROCE (%)	14.11	12.88	15.71	11.6	7.93	10.59	12.25	14.65	12.35	12.57
Asset Turnover Ratio	0.46	0.49	0.49	0.34	0.32	0.32	0.33	0.31	0.29	0.28
PAT to CFO Conversion(x)	0.34	0.69	0.98	1.56	2.94	5.57	0.45	1.45	0.25	1.43
Working Capital Days
Receivable Days	128	115	75	67	84	87	59	50	61	66
Inventory Days	119	109	102	110	96	95	92	100	112	112
Payable Days	103	86	73	129	168	191	184	186	156	165

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) Stock News

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) FAQs

What is the share price of Dishman Pharma(Amalg?

Company share prices are keep on changing according to the market conditions. The closing price of Dishman Pharma(Amalg on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Dishman Pharma(Amalg?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Dishman Pharma(Amalg stood at ₹4,858.8.

What is the P/E ratio of Dishman Pharma(Amalg?

The latest P/E ratio of Dishman Pharma(Amalg as of 01-Jan-1970 05:30 is 74.11.

What is the P/B ratio of Dishman Pharma(Amalg?

The latest P/B ratio of Dishman Pharma(Amalg as of 01-Jan-1970 05:30 is 1.02.

What is the 52-week high and low of Dishman Pharma(Amalg?

The 52-week high of Dishman Pharma(Amalg is ₹304.3 and the 52-week low is ₹278.1.

What is the TTM revenue of Dishman Pharma(Amalg?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dishman Pharma(Amalg is ₹416.8 ( Cr.) .

About Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the â€œQuat Companyâ€. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.

In the year 1995, the company entered into a joint ventured with SchÃ¼tz & Co, Germany and formed SchÃ¼tz Dishman Biotech. This company manufactures Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution to cater European market. In 1995-96, the company expanded its activities for the development of many intermediates and APIs. In 1998 in order to penetrate in European and US market, the company formed two wholly-owned subsidiaries Dishman Europe and Dishman USA Inc. In 1998, the company forayed into contract research and manufacture sector. Within a period of 5 years DPCL was able to several contract research and manufacturing projects and later emerged as Indiaâ€™s leading CMO organization (Contract Manufacturing Outsourcing).

Headquartered at Ahmedabad, the company owns three manufacturing units, two located at Bavla and one at Naroda. Presently the company is manufactures a range of Bulk APIs, Intermediates, Specialties and Quats. The company has representative office located at Germany, Italy and Turkey.

DPCL is engaged in the manufacture of active pharmaceutical ingredients (APIs) intermediates. The Company operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quats and specialty chemicals. It provides a range of products to the global market, including a range of reagents, specialty chemicals, APIs and their intermediates.

Business units:

Dishman Specialty Chemicals, which manufactures Phase Transfer Catalysts;

Dishman Vitamins and Chemicals, which manufactures Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and laolin related products for pharmaceutical, cosmetic and related markets,

Dishman Disinfectants, which manufactures antiseptic and disinfectant formulations.

The products manufactured by the company include bulk drugs, phase transfer catalyst and fine chemicals